Why does reimbursement of orphan drugs require a specific approach?
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
The greatest problem concerning the reimbursement of orphan products is their high price. In the case of orphan drugs, reimbursement and pricing decisions are highly interrelated. In decisions concerning reimbursement of newly marketed health technologies, their cost-effectiveness or cost-utility should be taken into account. Rigorousness and thoroughness of evaluating an orphan drug prior to a reimbursement or pricing decision should depend on the cost of treatment and it should be stressed that for most orphan interventions costs of treatment depends mainly on the price of the orphan product. Low cost orphan drugs should be managed as all other drugs which do not generate high treatment costs. In the case of high and very high cost orphan drugs much more restrictive procedures should be applied in its assessment. Apparently, assessment of a very high cost orphan drug should be performed and appropriate analyses should be prepared by the applicant. Alternatively, the technology may be assessed by the HTA Agency itself. Appraisal should be performed by a separate advisory body, e.g. The Rare Diseases Team to the Minister of Health. The final decision should be made by the Minister of Health, who will bear political responsibility. In Poland appropriate state authorities have to undertake specific professional pricing activities with respect to orphan products in egalitarian approach and introduce risk sharing agreements by Law.
Authors and Affiliations
Krzysztof Łanda, Jakub Adamski
Keywords
Related Articles
- EP ID EP53087
- DOI -
- Views 328
- Downloads 0
Znaczenie inhibitorów aromatazy w leczeniu chorych na raka piersi
Leczenie hormonalne raka piersi ma na celu ograniczenie oddziaływania endogennych estrogenów na komórki nowotworu. Odkrycie receptorów hormonalnych i poznanie ich znaczenia umożliwiło zastosowanie hormonoterapii w celowa...
Novel oral anticoagulants in the treatment of cancer patients
Cancer and its treatment are well-recognized risk factors for venous thromboembolism. The risk of thrombotic complications increases 4–7-fold in cancer patients and coexistence of both pathologies is associated with shor...
Rola eksemestanu w leczeniu raka piersi
Leczenie hormonalne jest jedną z podstawowych opcji terapeutycznych w leczeniu raka piersi, zarówno miejscowo zaawansowanego, jak i przerzutowego. Standardem od wielu lat pozostaje tamoksyfen, jednak wyniki nowych badań...
Sarcomatoid renal-cell carcinoma: treatment strategy, review of the literature and a case report
Introduction: Sarcomatoid renal-cell carcinoma is a very rare cancer characterised with aggressive course of disease and poor prognosis. At present there are no standards of care for this histologic subtype of renal cell...
Wczesna odpowiedź molekularna jako kryterium optymalnej odpowiedzi na leczenie przewlekłej białaczki szpikowej inhibitorami kinaz tyrozynowych
Obecnym celem leczenia przewlekłej białaczki szpikowej jest maksymalna redukcja liczby komórek białaczkowych z genem BCR/ABL i umożliwienie jak największej liczbie chorych osiągnięcia długotrwałej, głębokiej odpowiedzi m...